Scientific Online Resource System

Social Medicine

Прекласифициране на лекарствени продукти - поява и развитие на концепцията

В. Белчева, E. Григоров, И. Гетов

Abstract

Процесът на пререгистриране на лекарствени продукти от такива, отпускани по лекарско предписание, в лекарства без рецепта (OTC) в САЩ започва през 1972 г. и все още продължава. Oсновава се на поправката Durham-Humphrey от 1951 г., която изменя Федералния закон за храни, лекарства и козметика (FD&C), приет през 1938 г. Поради свободната им и широка достъпност, от значение е OTC лекарствата да се употребяват правилно и рационално, следователно да са свързани с ниска честота на сериозни нежелани лекарствени реакции или нежелани събития, както и нисък потенциал за увреждане в случай на злоупотреба.

Keywords

Reclassification, medicinal products, birth, concept

Full Text


References

Веков, Т. Социална фармация и фармацевтично законодателство. Учебник. Издателство на МУ-Плевен, 2014.

AESGP. The Economic and Public Health Value of Self-Medication. Brussels; 2004.

Aronson, JK. From prescription-only to over-the-counter medicines (`PoM to P'): Time for an intermediate category. Br Med Bull. 2009;90(1):63-9.

Black, N. Why we need observational studies to evaluate the effectiveness

of health care. BMJ. 1996; 12(7040):1215-1218.

Bond, C. The over-the-counter pharmaceutical market - policy and practice.

Eurohealth (Lond). 2008;14(3).

Burstein, A. Anatomy of a successful Rx-to-OTC switch. Med Mark Media.

;29(6):10-2.

Calvery, HO, Klumpp TG. The toxicity for human beings of diethylene glycol with sulfanilamide. South Med J. 1939;32:1105-9.

D'Agostino, RB, D'Agostino, RB. Estimating treatment effects using observational

data. JAMA. 2007;297(3):314-6.

Enns T, Damm K, Graf von der Schulenburg. Freier Preiswettbewerb auf dem deutschen OTC-Markt ... PharmacoEconomics Ger Res Artic. 2011;9(1):3-10

Feldman, M. Pros and cons of over-the-counter availability of histamine2-

receptor antagonists. Arch Intern Med. 1993;153(21):2415-24.

Gossel T. Implications of the reclassification of drugs from prescriptiononly

to over-the-counter status. Clin Ther. 1991;13(2):200-15; discus 199.

Hanks, GW. Nonprescription analgesics: a review of acetylsalicylic acid,

paracetamol, and phenacetin. Excerpta Medica; 1983.

Hlatky, M et al. Tying clinical research to patient care by use of an observational

database. Statistics in Medicine. 1984;3(4):375-384.

Hodgson R et al. Measurement of long-term outcomes in observational

and randomised controlled trials. Br J of Psychiatry. 2007;50.suppl:78-84.

Jacobs, LR. Prescription to over-the-counter drug reclassification. Am Fam

Physician. 1998;57(9):2209-14.

Juhl, RP. Prescription to over-the-counter switch: a regulatory perspective.

Clin Ther. 1998;20 Suppl C:C111-7.

Katzung, BG. Basic & Clinical Pharmacology [Internet]. Lange Medical

Books/McGraw Hill; 2004.

Mahecha, LA. Rx-to-OTC switches: trends and factors underlying success.

Nat Rev Drug Discov. 2006;5(5):380-5.

Pawaskar M, Balkrishnan R. Switching from prescription to over-the counter

medications: a consumer ... Manag Care Interface. 2007;20(1):42-7

Palumbo, FB. The impact of the Rx to OTC switch on practicing pharmacists.

Am Pharm. 1991;NS31(4):41-4.

Pray, WS, Worthen DB. A History of Nonprescription Product Regulation.

Taylor&Francis; 2003.

Rosenau, P. Medical Care Review. Health Administration Press; 1994.

Shiffman S, Gitchell J, Pinney J, Burton SL, et al. Public health benefit of

over-the-counter nicotine medications. Tob Control. 1997;21;6(4):306-10

Shiffman S, Sweeney C. Ten years after the Rx-to-OTC switch of nicotine

replacement therapy: what have we ...? Health Policy. 2008;86(1):17-26

Soller, RW. Evolution of self-care with over-the-counter medications. Clin

Ther [Internet]. Elsevier; 1998;19(20):C134-40.

Soller, RW. The Over-the-Counter Scientific/Regulatory Paradigm. Drug

Inf J. 1999;33(3):799-804.

Soller, R. Prescription-to-Over-the-Counter Switch Criteria. Drug Inf J.

;36:309-318.

Sullivan PW. Switching prescription drugs to over the counter: Consumers

may benefit financially in examples from the US. Br Med J. 2005; 330

(7496):904-5.

Synder, K. Rising tide - New wave of Rx-to-OTC switches coming. Drug

Topics. 1995;207:47-9.

Tasch, RF, Goeree R, Henke CJ, O`Brien BJ. Switching the histamine H2

receptor antagonist famotidine to nonprescription status in Canada. An

economic evaluation. Pharmacoeconomics. 1996;9(1):61-75.

Tisman, A. The Rising Tide of OTC in Europe: Trends, Challenges and

New Potential in a Rapidly Evolving Market. 2010;

USCHC. FDA`s Prescription to Over-the-counter Drug Switch: Hearing

Before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, Ninety-eighth Congress, First Session on the Food and Drug Admin. U.S. Gov Printing,1983.

Wax, PM. Elixirs, diluents, and the passage of the 1938 Federal Food,

Drug and Cosmetic Act. Ann Intern Med. 1995;122(6):456-61.

WHO. Guidelines for the Regulatory Assessment of Medicinal Products for Use in Self-medication. World Health Organization; 2000.

www.wsmi.org;

www.ecigintelligence.com




DOI: http://dx.doi.org/10.14748/sm.v1i3.1464

Refbacks

Font Size


|